KEYNOTE-028-NPC

NCT02054806 📎

Regimen

Experimental
Pembrolizumab 10 mg/kg IV every 2 weeks until progression or 2 years
Control
none

Population

PD-L1-positive (≥1%) recurrent or metastatic NPC previously treated with at least one prior line; 92.6% had received prior therapy for RM-NPC; 70.4% had ≥3 prior therapies

Key finding

KEYNOTE-028 established early proof-of-concept that PD-1 blockade with pembrolizumab has single-agent activity in heavily pretreated RM NPC. The 25.9% ORR in PD-L1-selected patients was promising enough to motivate the subsequent randomized KEYNOTE-122 trial. However, KEYNOTE-028 was a small, single-arm, PD-L1-selected cohort and does not constitute a definitive efficacy readout.

Source: PMID 28837405

Timeline

    Guideline citations

    • NCCN NPC (p.43)